- Home
- ERAS vs GTES Comparison
ERAS vs GTES Comparison
Compare ERAS & GTES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ERAS | GTES |
|---|---|---|
| Founded | 2018 | 1911 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 6.6B |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | ERAS | GTES |
|---|---|---|
| Price | $16.34 | $25.83 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 9 |
| Target Price | $14.25 | ★ $28.56 |
| AVG Volume (30 Days) | ★ 3.3M | 1.5M |
| Earning Date | 05-08-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 36.23 | 29.73 |
| EPS | N/A | ★ 0.90 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $5.83 |
| Revenue Next Year | N/A | $3.95 |
| P/E Ratio | ★ N/A | $28.83 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.53 | $20.88 |
| 52 Week High | $24.28 | $30.34 |
Technical Indicators
Market Signals| Indicator | ERAS | GTES |
|---|---|---|
| Relative Strength Index (RSI) | 40.99 | 45.46 |
| Support Level | $12.36 | $25.18 |
| Resistance Level | $18.71 | $26.82 |
| Average True Range (ATR) | 1.20 | 0.76 |
| MACD | -0.24 | -0.08 |
| Stochastic Oscillator | 15.04 | 46.83 |
Price Performance
Historical ComparisonAbout ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.
About GTES Gates Industrial Corporation plc
Gates Industrial Corp Ltd operates as a manufacturer of application-specific fluid power and power transmission solutions. Its product portfolio includes engineered components used in power transmission and fluid power applications across a range of end markets and geographic regions.